Global Hemostasis and Tissue Sealing Agents Market Overview
Hemostasis and Tissue Sealing Agents Market size was valued at USD 8.39 billion in 2023. The Hemostasis and Tissue Sealing Agents Market industry is projected to grow from USD 9.02 billion in 2024 to USD 18.19 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.04% during the forecast period (2024 - 2032). Growing incidences of road accidents and chronic blood disorders, Growing preference of minimally invasive procedures globally, and the growing elderly population are driving the market growth.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Hemostasis and Tissue Sealing Agents Market Trends
- Growing incidences of road accidents and chronic blood disorders is to boost the market growth
The growing incidence of chronic blood disorders is another factor propelling the market's expansion. Individuals with certain blood disorders, such as hemophilia or von Willebrand disease, have an increased risk of bleeding due to impaired clotting factors. Hemostasis agents, which promote blood clotting and control bleeding, may be essential in surgical procedures or medical interventions for individuals with these disorders. For instance, according to the International Society on Thrombosis and Hemostasis' 2022 update, around 10 million cases of venous thromboembolism occur globally each year. According to the same source, 544,000 people in Europe die each year as a result of Deep Vein Thrombosis (DVT). According to PhRMA's Disorders of the Blood 2022 report, which was published in May 2022, over 3.2 million Americans suffer from a bleeding disorder each year. Some blood disorders may necessitate surgical interventions for treatment or management. Patients undergoing surgeries may require hemostasis agents to control bleeding during and after the procedure. Tissue sealing agents may also be used to facilitate wound closure. As a result, a growth in the number of patients with blood disorders, combined with a growing requirement to treat a variety of bleeding problems, is expected to fuel the demand for hemostasis and tissue-sealing agents.
Hemostasis and Tissue Sealing Agents Market Segment Insights
Hemostasis and Tissue Sealing Agents Product Insights
The Hemostasis and Tissue Sealing Agents Market segmentation, based on Product, includes Topical Hemostat, and adhesive & tissue sealant. The Topical Hemostat segment is to hold the majority share in 2023 in the Hemostasis and Tissue Sealing Agents Market revenue. This is because of the rising number of surgical procedures and trauma cases, advancements in technology improving product efficacy, and the aging population increasing the need for surgeries. Additionally, the cost-effectiveness of topical hemostats, favorable regulatory approvals, and market expansion in emerging economies contribute significantly to their demand.
Hemostasis and Tissue Sealing Agents Material Insights
The Hemostasis and Tissue Sealing Agents Market segmentation is based on a material that includes Chitosan-based Products and Mineral based Products. The Mineral based Products segment has dominated the market in 2023 and Chitosan-based Products is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is due to chitosan, derived from chitin found in shellfish, is biocompatible, biodegradable, and non-toxic, making it an attractive choice for medical and pharmaceutical applications. Its excellent hemostatic properties, which enable rapid blood clotting, are highly valued in wound care and surgical procedures.
Figure 2: HEMOSTASIS AND TISSUE SEALING AGENTS MARKET, BY APPLICATION, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Hemostasis and Tissue Sealing Agents End User Insights
The Hemostasis and Tissue Sealing Agents Market segmentation is based on end-user that includes Hospitals, Ambulatory Surgical Centers, and Research Institutes. The Hospitals segment has dominated the market in 2023 and Ambulatory Surgical Centers is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is due to Ambulatory Surgical Centers are cost-effective alternative to traditional hospital-based surgeries, providing significant savings for both patients and insurers. ASCs typically have lower overhead costs, which translates to reduced procedure costs which will drive the demand.
Hemostasis and Tissue Sealing Agents Regional Insights
By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Hemostasis and Tissue Sealing Agents market accounted for the largest market share in 2023. Due to aging population, increasing prevalence of chronic diseases, and the continuous evolution of medical technology. With a focus on enhancing patient outcomes and reducing postoperative complications, the market has become a hub for research and development, resulting in the introduction of innovative products with superior efficacy. In 2019, Ethicon (US) introduced VISTASEAL Fibrin Sealant (Human) to manage bleeding during surgery. VISTASEAL Fibrin Sealant (Human) contains fibrinogen and thrombin, which are clotting proteins found in human plasma. When applied to the bleeding site, it forms a rapid, adherent, and durable clot. It has been demonstrated to sustain hemostasis (stoppage of bleeding), even in high-risk patients.
Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Europe Hemostasis and Tissue Sealing Agents market is expected to account for the second-largest market share due to the favorable health policies and trend towards integrating Hemostasis and tissue sealing agents, including counseling. Further, the German Hemostasis and Tissue Sealing Agents market was attributed to holding the largest market share, and France Hemostasis and Tissue Sealing Agents market is expected to fastest-growing market in the European region.
The Asia-Pacific Hemostasis and Tissue Sealing Agents market is expected to grow at the fastest rate from 2024 to 2032. This is due to rapid economic development, a burgeoning middle class, and increased urbanization. The region's expanding population drives demand for healthcare, technology, and consumer goods. Robust investments in infrastructure, education, and technology fuel industrial growth and innovation. Additionally, favorable government policies and trade agreements enhance business opportunities and foreign investment. The rise of digital economies and advancements in technology, particularly in countries like China, India, and South Korea, further stimulate growth.
The Rest of the World includes the Middle East, Africa, and Latin America. The main factors influencing the growth of Hemostasis and Tissue Sealing Agents in the Middle East and Africa. MEA region has experienced Increasing healthcare expenditure, and the expansion of healthcare infrastructure are driving demand for advanced medical products. The rise in surgical procedures, fueled by a growing population and higher prevalence of chronic diseases, necessitates effective hemostasis solutions.
Hemostasis and Tissue Sealing Agents Key Market Players & Competitive Insights
The Hemostasis and Tissue Sealing Agents Market is characterized by the presence of many global, regional, players. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reached across the globe with diverse Type portfolios. Companies such Johnson & Johnson (US), B Braun Medical Inc (Germany), MIL Laboratories Pvt. Ltd (India), Becton, Dickinson, and Company (US), and Pfizer Inc (US) dominate the Hemostasis and Tissue Sealing Agents Market due to Type differentiation, financial stability, strategic services, and diversified regional presence. The players are focused on investing in extensive research and development as well. Furthermore, they adopt strategic growth initiatives, such as expansion, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.
One of the primary business strategies adopted by manufacturers in the global Hemostasis and Tissue Sealing Agents industry to benefit clients and expand the Hemostasis and Tissue Sealing Agents market sector is to manufacture locally to reduce operating costs.
Key Companies in the Hemostasis and Tissue Sealing Agents Market include
- B Braun Medical Inc (Germany)
- MIL Laboratories Pvt. Ltd (India)
- Becton, Dickinson, and Company (US)
- Teleflex Incorporated (US)
- Medtrade Products Limited (UK)
- Axio Biosolutions Pvt Ltd (India)
Hemostasis and Tissue Sealing Agents Industry Developments
November 2023, The Johnson & Johnson MedTech company Ethicon (US) introduced ETHIZIA, an adjuvant hemostat product. ETHIZIATM Hemostatic Sealing Patch is the first and only hemostatic matrix designed to be equally active and effective on both sides. The product is easy to use in open and minimally invasive surgical procedures.
In June 2021, Axio Biosolutions Pvt Ltd (India) received FDA 510(k) clearance for Axiostat Patch, a hemostatic medication that controls moderate to severe bleeding during vascular operations, surgical debridement, and puncture sites
In January 2020, Medtrade Products Limited launched OMNI-STAT 2/3in x 4 3/4 Hemostatic Gauze. OMNI-STAT hemostatic gauze is a non-woven gauze pad laminated on both sides with proprietary chitosan granule technology, designed to quickly control bleeding.
Hemostasis and Tissue Sealing Agents Market Segmentation
Hemostasis and Tissue Sealing Agents Products Outlook
-
Adhesive & Tissue Sealant
- Adhesion Barrier Products
Hemostasis and Tissue Sealing Agents Material Outlook
Hemostasis and Tissue Sealing Agents End User Outlook
- Minimally Invasive Surgery
Hemostasis and Tissue Sealing Agents End User Outlook
-
Ambulatory Surgical Centers- Independent Ambulatory Surgical Centers
- Military Ambulatory Surgical Centers
Hemostasis and Tissue Sealing Agents Regional Outlook
|
Report Attribute/Metric
|
Details
|
|
Market Size 2023
|
USD 8.39 billion
|
|
Market Size 2024
|
USD 9.04 billion
|
|
Market Size 2032
|
USD 18.19 billion
|
|
Compound Annual Growth Rate (CAGR)
|
8.04% (2024-2032)
|
|
Base Year
|
2023
|
|
Forecast Period
|
2024-2032
|
|
Historical Data
|
2019 to 2022
|
|
Forecast Units
|
Value (USD Billion)
|
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
|
Segments Covered
|
Product, Material, End User, and Region
|
|
Geographies Covered
|
North America, Europe, Asia Pacific, and the Rest of the World
|
|
Countries Covered
|
The US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
|
|
Key Companies Profiled
|
Johnson & Johnson (US), B Braun Medical Inc (Germany), MIL Laboratories Pvt. Ltd (India), Becton, Dickinson, and Company (US)
Pfizer Inc (US), Teleflex Incorporated (US), Medtronic (Ireland), Baxter (US), Medtrade Products Limited (UK), Axio Biosolutions Pvt Ltd (India)
|
|
Key Market Opportunities
|
Rising Technological Advancements
Increasing healthcare investments
|
|
Key Market Dynamics
|
Growing incidences of road accidents and chronic blood disorders
Growing preference of minimally invasive procedures globally
Growing elderly population are driving the market growth.
|
Hemostasis Tissue Sealing Agents Market Highlights:
Frequently Asked Questions (FAQ) :
The Hemostasis and Tissue Sealing Agents Market is anticipated to reach 18.19 billion at a CAGR of 8.04% during the forecast period of 2024-2032.
The US is expected to hold a 70-80% share of the North American market for the Hemostasis and Tissue Sealing Agents market during the forecast period of 2024-2032.
The Hemostasis and Tissue Sealing Agents market is expected to grow at a 8.04% CAGR during the forecast period from 2024 to 2032.
The North American region market held the largest market share in the Hemostasis and Tissue Sealing Agents market.
The key players include Johnson & Johnson (US), B Braun Medical Inc (Germany), MIL Laboratories Pvt. Ltd (India), Becton, Dickinson, and Company (US), Pfizer Inc (US), Teleflex Incorporated (US), Medtronic (Ireland), Baxter (US), Medtrade Products Limited (UK), Axio Biosolutions Pvt Ltd (India).
The General Surgery segment was estimated to lead the Hemostasis and Tissue Sealing Agents market.
The Hospitals segment is attributed to having the largest market share based on end user.
